2018
DOI: 10.1200/jco.2018.36.15_suppl.e18042
|View full text |Cite
|
Sign up to set email alerts
|

Predicting unreported clinical trial efficacy using an ex-vivo tumor platform: Pembrolizumab+pt+5-FU vs. extreme in recurrent head and neck squamous cell carcinoma.

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles